All In Biotech

Drug Trial Radar · NCT07564414

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

May 21, 2026

Primary completion

Feb 23, 2028

Study completion Apr 19, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

Conditions

  • Obesity
  • Type 2 Diabetes

Interventions

  • CagrisemaDrug

    Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.

  • SemaglutideDrug

    Semaglutide will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in body weightTime frame: From randomisation (week 0) to end of treatment (week 72)

Locations

303 sites in 19 countries. Site status is shown where the registry gives one.

  • Uni of Alabama at Birmingham

    Birmingham, Alabama · Active not recruiting

  • Cahaba Research

    Pelham, Alabama · Active not recruiting

  • Elligo Health Research Inc

    Gilbert, Arizona · Active not recruiting

  • Velocity Clinical Research-Phoenix

    Phoenix, Arizona · Active not recruiting

  • Arkansas Clinical Research

    Little Rock, Arkansas · Active not recruiting

  • Woodland Int. Research Group

    Little Rock, Arkansas · Active not recruiting

  • Headlands Research California, LLC

    Escondido, California · Active not recruiting

  • Neighborhood Healthcare

    Escondido, California · Active not recruiting

  • Diabetes & Endocrine Specialists - La Mesa

    La Mesa, California · Active not recruiting

  • Clinical Trials Research_Sacramento

    Lincoln, California · Active not recruiting

  • Loma Linda University Faculty Medical Clinics

    Loma Linda, California · Active not recruiting

  • Pacific Clinical Studies

    Los Alamitos, California · Active not recruiting

  • Valley Clinical Trials

    Northridge, California · Active not recruiting

  • Desert Oasis Healthcare

    Palm Springs, California · Active not recruiting

  • Linda Vista Health Care Ctr

    San Diego, California · Active not recruiting

  • Velocity Clin Res - Van Nuys

    Van Nuys, California · Active not recruiting

  • Flourish Research - CA

    Walnut Creek, California · Active not recruiting

  • University of Colorado Hospital

    Aurora, Colorado · Completed

  • TBMR & Alcanza

    Clearwater, Florida · Active not recruiting

  • Northeast Research Institute

    Fleming Island, Florida · Active not recruiting

  • Northeast Research Institute

    Jacksonville, Florida · Active not recruiting

  • Westside Center For Clinical Research

    Jacksonville, Florida · Active not recruiting

  • Bioclinical Research Alliance

    Miami, Florida · Active not recruiting

  • New Horizon Research Center

    Miami, Florida · Active not recruiting

  • South Broward Research LLC

    Miramar, Florida · Active not recruiting

  • West Orange Endocrinology

    Ocoee, Florida · Active not recruiting

  • Oviedo Medical Research, LLC

    Oviedo, Florida · Active not recruiting

  • Clinical Trial Services Corp

    Pembroke Pines, Florida · Active not recruiting

  • Hope Clin Res & Wellness

    Conyers, Georgia · Active not recruiting

  • Center for Adv Res & Education

    Gainesville, Georgia · Active not recruiting

  • Endocrine Research Solutions, Inc

    Roswell, Georgia · Active not recruiting

  • North Georgia Clinical Research

    Woodstock, Georgia · Active not recruiting

  • Solaris Clinical Research

    Meridian, Idaho · Active not recruiting

  • Cedar-Crosse Research Center

    Chicago, Illinois · Active not recruiting

  • Macoupin Fam Practice Ctr, LLP

    Gillespie, Illinois · Active not recruiting

  • Clinical Investigation Spec Gurnee

    Gurnee, Illinois · Active not recruiting

  • Endeavor Health

    Skokie, Illinois · Active not recruiting

  • Evanston Premier Hlthcr Res

    Skokie, Illinois · Active not recruiting

  • Iowa Diabetes Research

    West Des Moines, Iowa · Active not recruiting

  • Alliance for Multispecialty Research

    Newton, Kansas · Active not recruiting

Showing 40 of 303 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.